Could a change in global policy be the best way to start research into the medical potential of psilocybin?
A new movement for international psychedelic reform has been set in motion. A global coalition made up of the Beckley Foundation, the Multidisciplinary Association for Psychedelic Studies (MAPS), the Drug Science and Open Foundation and the agency Mind Medicine Australia launched this Push last Tuesday.
Psychedelics have been banned in the United States and around the world for several decades. This new decade seems to usher in hopes for the decriminalization and medical use of psychedelics. The global coalition hopes to change international policies banning the magic drug. Get psilocybin mushrooms internationally postponed may encourage U.S. lawmakers to follow suit.
Tired of dragging your feet
Proponents have repeatedly spoken out about having a bill that allows the use of psychedelics to treat certain illnesses. However, US lawmakers did a lot of foot-dragging instead. Last year, a bill was finally approved to allow a limited level of research into the drug’s therapeutic potential.
The International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) has begun its campaign for psychedelic reform. The organization is committed to rescheduling these banned substances following the 1971 United Nations Convention on Psychotropics. This 1971 policy places psilocybin as the most harmful drug on the list, hence the strict restriction on the psychedelic drug. In the United States, psilocybin also falls into the Schedule 1 category. Many proponents of psychedelics and cannabis believe that this classification should be reserved for “hard” drugs that pose serious health risks to people, regardless of their level. region – Drugs with little or no known medicinal benefit.
Recent developments have proven that psilocybin or magic mushrooms do not fit the criteria for Schedule I substances. The world organization has pointed out that psilocybin is wrongly subject to severe limits despite its medical potentials. An important point raised at the convention is that psilocybin could be licensed, safely manufactured in limited quantities (to begin with), and imported or exported based on acceptable regulations. It’s better than the crude oversight of the industry by international bodies.
A boost for more research
If this push is successful, Appendix I researchers can study psilocybin, magic mushroom, LSD, and other related psychedelics. To do so, these scientists will also have to deal with international regulations. These obstacles will not come cheap, adding additional cost and complexity to the search. Banning the substance by governments around the world can negatively impact ethical approvals, collaborations, and funding.
The first step to properly launching this new measure will be to connect with member countries that are among the treaty signatories to begin a formal review of its position against psilocybin and other psychedelics. This review will shed light on the benefits and risks of the drug. To initiate the process, a country must request a review from the World Health Organization (WHO).
The WHO itself could also initiate the procedure. Once the request has been made and approved, the international body. The Executive Committee on Drug Dependence (ECDD) would initiate the review process. Recommendations on policy changes will be proposed by member countries. Any revision that obtains the support of two-thirds of the signatory countries would be enacted, whether or not it involves a rescheduling recommendation.
Christopher Koddermann, chairman of the board and co-founder of ITPRI, said in a press release that a change in psilocybin’s status as a Schedule I drug is well overdue. He added that there is a better scientific understanding of the substance’s high therapeutic potential and low addiction possibilities. “It’s enough to turn the tide,” he explained.
Member States likely to initiate proceedings
ITPRI says it has identified a dozen countries willing to offer a review to reschedule psilocybin around the world. According to Mr. Koddermann, Canada is the most suitable option among the choices available. Canada is one of the few countries to have fully decriminalized and legalized cannabis (a Schedule I substance). The country has also relaxed its restrictions on the use of entheogen for critically ill patients.
Founder of partner ITPRI Drug Science and Director of the Center for Psychedelic Research at Imperial College London, David Butt, highlighted the coalition’s shared view that existing international psilocybin programming seriously restricts development progress. of treatments for neurology patients with the drug.
Willem Scholten, former WHO ECDD secretary and ITPRI advisory board member, added that the 1971 convention policy review is a game-changing chance to move the psilocybin industry forward. This will accelerate the creation of drugs that will change the lives of patients, as well as the search for other medical potentials of the drug.
The fears of the coalition
As much as one member country can initiate this review process, another can oppose it. Recently, the WHO maintained its position against the prescription of Krotom (a plant well known for its analgesic potential). This decision was made despite the results of a scientific examination of the plant. ITPRI is concerned that the WHO’s ECDD will do the same if a deferral recommendation is made for psilocybin. On Kratom, the WHO could have offered a more critical review which could have resulted in a postponement, or it could have convinced member countries to regulate the drug.
In 2020, the United Nations Commission on Narcotic Drugs authorized a WHO recommendation to remove cannabis from the most restrictive international programming category.
Psychedelics in the United States
While the international coalition is working tirelessly to advance the policy review initiative, pro-psychedelic groups in the United States are also working tirelessly to initiate reforms to existing federal policies regarding plants such as psilocybin or mushrooms. magical.
At the same time, bills are introduced in the Senate and the House to end the prohibition of cannabis. Cannabis and psychedelic reforms are gradually catching the attention of the Biden administration.
Representative Earl Blumenauer sought the cooperation of the DEA to legally allow patients to use psilocybin without fear of federal repercussions. He added that the drug would be used as an experimental treatment in ongoing clinical trials.
Millions of people around the world are excited about recent advances in psychedelic research. Many of these incredible feats will be followed by shifts in international and domestic policy.
UN TREATIES ON DRUG READ MORE..
#Psilocybin #Mushrooms #Rescheduled #Drug #Treaties #Marijuana #Wait